成人急性淋巴细胞白血病的诊断、预后因素与评估:欧洲专家小组2024年ELN推荐
欧洲白血病网工作组发布2024年成人急性淋巴细胞白血病共识推荐,涵盖诊断方法、生物学与临床特征、预后因素、风险分层及终点与结局定义,治疗与支持治疗另文发表,旨在指导成人患者初始管理并奠定未来协作研究基础。
要点
- 该推荐涵盖成人ALL的诊断方法、生物学与临床特征、预后因素及风险分层。
- 推荐同时定义了终点与结局,治疗及支持治疗内容另文发表。
- 推荐旨在为成人ALL初始管理提供指导并奠定未来协作研究基础。
核心结论
- 该推荐旨在为成人ALL患者的初始管理提供指导,并定义作为未来协作研究基础的原则。
研究设计与样本
- 欧洲白血病网工作组发布共识推荐,总结成人ALL诊断方法、生物学与临床特征、预后因素、风险分层及终点与结局定义的当前最新水平。
主要发现
- 成人ALL具有许多不同的临床和生物学亚组,疾病生物学与治疗选择的知识呈指数增长。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Working groups of the European LeukemiaNet have published several important consensus guidelines. Acute lymphoblastic leukemia (ALL) has many different clinical and biological subgroups and the knowledge on disease biology and therapeutic options is increasing exponentially. The European Working Group for Adult ALL has therefore summarized the current state of the art and provided comprehensive consensus recommendations for diagnostic approaches, biologic and clinical characterization, prognostic factors, and risk stratification as well as definitions of endpoints and outcomes. Aspects of treatment, management of subgroups and specific situations, aftercare, and supportive care are covered in a separate publication. The present recommendation intends to provide guidance for the initial management of adult patients with ALL and to define principles as a basis for future collaborative research.
引用
- Gökbuget N, Boissel N, Chiaretti S, et al. Diagnosis, prognostic factors, and assessment of ALL in adults: 2024 ELN recommendations from a European expert panel. Blood. 2024. PMID: 38295337. doi:10.1182/blood.2023020794
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。